In summary, we have developed a VEGF115-CPG2(Q)3-H6 fusion protein that is highly expressed, efficiently secreted, has a high specific activity, binds rapidly to its target, can direct prodrug cytotoxicity to VEGFR2-expressing cells, and is a candidate for a new approach to cancer therapy. The gene discussed is KDR; the disease is cancer.